Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2015-003183-36-CZ
EUCTR2015-003183-36-CZActive, not recruitingPhase 1

A randomized parallel group phase III trial of OSE 2101 as 2nd or 3rd line compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic (IV) Non-Small-Cell Lung Cancer. (OSE2101C301) - ATALANTE 1

OSE Immunotherapeutics0 sites325 target enrollmentStarted: November 12, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
325
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Protection of study subjects and compliance
  • •1. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
  • •2. Willingness and ability to comply with scheduled visits, treatment
  • •plans, laboratory tests, and other study procedures.
  • •3. Female or male, 18 years of age or older.
  • •Cancer Diagnosis and treatment
  • •4. Histologically or cytologically proven diagnosis of NSCLC that is locally advanced (stage IIIB unsuitable for radiotherapy or metastatic (stage IV) according to the 7th edition of tumor, node, metastasis (TNM) in Lung Cancer published by the International Union Against Cancer and
  • •the American Joint Committee on Cancer.
  • •5. Subjects with disease recurrence or progression
  • •After therapy with an immune checkpoint inhibitor and platinum based chemotherapy:
  • •- either 1st line chemotherapy followed by 2nd line checkpoint inhibitor,
  • •- or 1st line combination of checkpoint inhibitor and chemotherapy
  • •6. Subjects with measurable or non-measurable lesions.
  • •7. Subjects must express HLA-A2 phenotype as assessed serologically.
  • •8. Subjects must be considered suitable for chemotherapy with either single-agent pemetrexed or docetaxel.
  • •9. Subjects with brain metastases are eligible if treated (whole brain radiotherapy, stereotaxic radiotherapy, surgery) and have no symptoms
  • •(except for signs and symptoms related to central nervous system therapy) for at least 2 weeks before initiation of allocated treatment and are not taking any forbidden medications (refer to section 4.3.5).
  • •10. Any prior chemotherapy, immunotherapy, radiation therapy or surgeries must have been completed at least 3 weeks prior to initiation of study medication.
  • •11. Any toxicity from prior therapy must have recovered to = Grade 1 (except alopecia).
  • •Clinical status
  • •12. ECOG performance status 0-1.
  • •13. Adequate organ function as defined by all the following criteria:
  • •a. Albuminemia > 25g/L
  • •b. Serum aspartate transaminase (AST) and serum alanine transaminase
  • •(ALT) = 1.5 x upper limit of normal (ULN) with alkaline phosphatase = 2.5 x ULN, or AST and ALT = 5 x ULN if liver function abnormalities are due to liver metastases
  • •c. Total serum bilirubin = 1.5 x ULN
  • •d. Absolute neutrophil count (ANC) = 1500/microliters
  • •e. Platelets 100000/microliters
  • •f. Hemoglobin = 9.0 g/dL (in the absence of transfusion within 2 weeks before randomization)
  • •g. Creatinine clearance (based on modified Cockcroft-Gault formula) =
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 200
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 125

Exclusion Criteria

  • •Cancer Diagnosis and treatment
  • •1. Small-cell lung cancer/mixed NSCLC with small cell component or other neuroendocrine lung cancers (typical and atypical carcinoids, large-cell neuroendocrine carcinomas). Large-cell carcinoma.
  • •2. NSCLC that is predominantly squamous cell carcinoma, and patient had docetaxel as part of his prior chemotherapy.
  • •3. Current or previous treatment with investigational therapy in another
  • •therapeutic clinical trial interrupted less than 4 weeks before study
  • •treatment initiation.
  • •4. Patients whose tumor harbors EGFR gene mutation that sensitizes tumors to TKI (EGFR exon 18-21) or ALK rearrangement.
  • •5. Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy that would be scheduled to continue concomitantly to the study).
  • •6. Spinal cord compression (unless treated with the patient attaining good pain control and stable or recovered neurologic function), carcinomatous meningitis, or leptomeningeal disease
  • •7. Patients with squamous cell histology or non-squamous cell histology previously treated by pemetrexed and with a contraindication for docetaxel with grade = 2 neuropathy or hypersensitivity reaction to medications formulated with polysorbate 80 (Tween 80) as they could be randomly assigned to Arm B.
  • •Medical history and clinical status
  • •8. Patients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications.
  • •9. Treatment with corticosteroids in the last 3-week period before inclusion, except for topical, ocular, intra-articular, intranasal, and inhaled corticosteroids with minimal systemic absorption (e.g. with a dose = 500 microgram beclomethasone equivalent for inhaled steroids),
  • •or adrenal replacement steroid doses = 10 mg daily prednisone equivalent which are permitted.
  • •10. A recognized immunodeficiency disease including human
  • •immunodeficiency virus (HIV) infection (and other cellular
  • •immunodeficiencies, hypogammaglobulinemia or
  • •dysgammaglobulinemia; subjects who have hereditary, congenital or
  • •acquired immunodeficiencies).
  • •11. Patients with auto-immune disease, with the exception of type I
  • •diabetes or treated hypothyroidism.
  • •12. Patients with interstitial lung disease.
  • •13. Patients with active B or C hepatitis.
  • •14. Other malignancy: patients will not be eligible if they have evidence
  • •of active malignancy (other than non-melanoma skin cancer or localized
  • •cervical cancer, or localized and presumed cured prostate cancer).
  • •15. Other severe acute or chronic medical or psychiatric conditions, or
  • •laboratory abnormalities that would impart, in the judgment of the
  • •investigator and/orsponsor, excess risk associated with study
  • •participation or study drug administration, and which would, therefore,
  • •make the patient inappropriate for entry into this study.
  • •16. Female patients must be surgically sterile or be postmenopausal, or
  • •must agree to use effective contraception during the period of the trial
  • •and for at least 90 days after completion of treatment (See APPENDIX 7
  • •GUIDANCE ON CONTRACEPTION in the protocol)
  • •17. Male patients sexually active with a woman of childbearing potential
  • •must be surgically sterile or must agree to use effective contraception
  • •during the period of the trial and for at least 90 days after completion of
  • •treatment. The decision of effective contraception will be based on the
  • •judgment of the principal investigator (See APPENDIX 7 GUIDANCE ON
  • •CONTRACEPTION in the protocol)
  • •18. Breastfeeding women.

Investigators

Similar Trials

Active, not recruiting
Phase 1
A randomized, parallel group, phase III study to compare OSE 2101 with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with advanced Non-Small-Cell Lung Cancer after failure of immune checkpoint inhibitors.on-Small-Cell Lung CancerMedDRA version: 21.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864
EUCTR2015-003183-36-DEOSE Immunotherapeutics494
Active, not recruiting
Phase 1
A randomized, parallel group, phase III study to compare OSE 2101 with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) who are unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer.on-Small-Cell Lung Cancer
EUCTR2015-003183-36-ESOSE Pharma500
Active, not recruiting
Phase 1
A randomized, parallel group, phase III study to compare OSE 2101 with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) who are unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer.on-Small-Cell Lung CancerMedDRA version: 20.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864
EUCTR2015-003183-36-PLOSE Immunotherapeutics325
Active, not recruiting
Phase 1
A randomized, parallel group, phase III study to compare OSE 2101 with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) who are unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer.
EUCTR2015-003183-36-SIOSE Immunotherapeutics500
Active, not recruiting
Phase 1
A randomized, parallel group, phase III study to compare OSE 2101 with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) who are unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer.
EUCTR2015-003183-36-HUOSE Immunotherapeutics500
A randomized, parallel group, phase III... | Clinical Trial